Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
  • Platform
  • Pipeline
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Connect

Press Releases

Third Quarter 2026 Earnings Conference Call  Click Here

To view our PMN310 Scientific and Clinical Update (November 2026)   Click Here

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Oct 22, 2021

ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors

Oct 21, 2021

ProMIS Neurosciences Files Special Meeting Proxy Material

Oct 7, 2021

ProMIS Neurosciences Announces Special Shareholder Meeting

Sep 15, 2021

ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021

Sep 13, 2021

ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference

Sep 1, 2021

ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors

Aug 25, 2021

ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering

Aug 18, 2021

ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M

Aug 18, 2021

ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units

Aug 17, 2021

ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units

  • arrow_back
  • 1…
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • …28
  • arrow_forward
Linkedin Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy

Disclaimer

All statements and expressions are the sole opinion of the company and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.